Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study developed a guideline for diagnosing and treating alopecia areata, revealing that 0.21% of the German population had the condition in 2020, with approximately 70,000 new cases diagnosed that year.

This study found that an earlier onset of androgenetic alopecia, especially in a frontal balding pattern, was significantly associated with an increased risk of prostate cancer among men at a Veterans Affairs Hospital.

This study found significantly higher levels of the protein ULBP3 in patients with alopecia areata incognita compared to other hair loss conditions and healthy controls, suggesting ULBP3's potential as a diagnostic marker for AAI.

This study reported that a large proportion of US adults with physician-diagnosed alopecia areata experience substantial emotional and mental health comorbidities and report significant stigma across all disease severities, yet few are receiving counseling or therapeutic intervention.

This case report observed hair regrowth following the treatment of alopecia universalis and atopic dermatitis with tofacitinib, a JAK inhibitor.

This review discusses alopecia areata, highlighting its autoimmune aspects, environmental triggers, and current treatment options, but reports no new clinical results; recent studies suggest JAK pathway intervention may offer therapeutic potential.

This study examined genetic risk factors for alopecia areata in the Jordanian population but found no significant association between the 21 targeted risk loci and the condition, emphasizing variability in genetic predisposition across ethnic groups and potential non-genetic triggers.

This article discusses alopecia areata, highlighting its autoimmune nature and the lack of FDA-approved treatments, without providing new research findings.

This study found that line-field confocal optical coherence tomography effectively visualized microscopic alterations in alopecia areata, suggesting its potential use in diagnosis and monitoring.

This review discusses the use of animal models to study alopecia areata and reports no new experimental results, emphasizing the potential for these models to explore the disease's genetics and treatment.

This study found that a combination therapy of oral corticosteroid and oral PUVA led to scalp hair regrowth in patients with intractable alopecia totalis and universalis within two months.

This study highlights alopecia areata incognita as a unique form of alopecia areata that shares features with telogen effluvium and may relate to androgenetic alopecia, noting its sudden onset and favorable response to topical steroids.

This correspondence discusses the treatment of alopecia universalis in a 6-year-old girl using simvastatin/ezetimibe, minoxidil, and prednisolone, but it reports no new clinical findings.

This article discusses the prevalence of alopecia areata in patients undergoing hair transplant surgeries and reports no new research findings.

This review discusses recent advancements made in using mouse models to investigate the genetic complexity and pathogenesis of alopecia areata, emphasizing potential new treatment targets, but it reports no new findings.

A comprehensive approach is needed to accurately assess alopecia areata severity and guide treatment decisions.

This article reviews the characteristics, associations, and diagnostic criteria for alopecia areata and reports no new clinical findings; the authors note the disease's unpredictable course and variable prognosis.

Alopecia areata patients often have low vitamin D levels.

This study found that African American men with prostate cancer have higher rates of somatic and germline androgen receptor mutations than Caucasian American men, which may contribute to ethnic differences in disease progression and outcomes.

This review examines the outcomes of treating Brazilian patients with alopecia universalis using tofacitinib and highlights the need for randomized controlled trials to determine optimal dosing and duration.

This study detailed the implementation of an autonomous AI device in an NHS skin cancer pathway, showing that it achieved a sensitivity of 97.3% for diagnosing skin cancers and exceeded sensitivity targets compared to specialists with a negative predictive value over 99.7%.

This review highlights advancements in the understanding and treatment of alopecia areata, noting that the approval of oral Janus kinase inhibitors like baricitinib and ritlecitinib marks a significant development in managing severe cases of this autoimmune condition.

This discussion highlights that alopecia areata incognita is challenging to diagnose and treat, with systemic corticosteroids potentially leading to remission when local treatments fail.

This study found that individuals with Alopecia Areata had distinct gut microbiome characteristics, including reduced species richness and specific microbial biomarkers, suggesting a potential link with oxidative stress.

This case study reported that acupuncture therapy successfully resolved long-standing alopecia areata in a 61-year-old male after nine months of treatment, suggesting potential efficacy without pharmacological intervention.

This study reports that AhR pathway expression is significantly reduced in lymphocytes of alopecia areata patients, suggesting its potential as a diagnostic marker and therapeutic target.

Abrocitinib may help treat alopecia areata effectively with mild side effects.

This review reports that alopecia areata negatively affects sexual functioning, highlighting the need for further research due to limitations in current study sizes and populations.

This review highlights novel treatment options for alopecia areata, focusing on nanoparticulate drug-delivery systems to improve the effectiveness and targeting of therapies for this complex autoimmune condition.